Efficacy and safety of Brivaracetam as adjunctive therapy in pediatric epilepsy: A systematic review and meta-analysis
Neurological Sciences · 2025
DOI: 10.1007/s10072-025-08185-9 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Neurological Sciences, 2025. Verfasst von Malak A Hassan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Alexandria University, Alexandria, Egypt. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsy, Pyrrolidinones. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Al-Azhar University.
Abstract (Originalsprache)
Background
Brivaracetam is a novel third-generation antiseizure medication and an analog of levetiracetam with selective affinity for synaptic vesicle protein 2A (SV2A). By binding SV2A, brivaracetam decreases pre-synaptic neurotransmitter release.
Aim
We aimed to assess the safety and efficacy of brivaracetam in pediatric epilepsy.
Method
We searched PubMed, Scopus, and Web of Science (WOS) for relevant clinical and observational studies from inception until February 2024. We carried out statistical analysis using Open Meta-Analyst. Dichotomous data were pooled as proportions with a 95% confidence interval (CI).
Results
Eleven studies with a total of 805 patients were identified. The analysis of four studies revealed the more than 50% responder rate in a cohort of 252 focal epilepsy patients to be 51.5% (95% CI: [32.6%, 70.5%]). The analysis of three studies involving a cohort of 266 patients found a 20.7% incidence (95% CI: [15.8%, 25.6%]) of complete seizure freedom. The analysis of nine studies involving a cohort of 737 epilepsy patients revealed a retention rate of 66% (95% CI: [40%, 92%]).
Conclusion
This study highlights the efficacy, tolerability, and safety of brivaracetam as adjunctive therapy in pediatric patients with epilepsy. The findings support its consideration as a valuable treatment option for children and adolescents, particularly those with drug-resistant epilepsy. Further trials with longer follow-up durations are needed to study the optimal doses and explore factors affecting drug response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Alexandria University, Alexandria, Egypt.
- Faculty of Medicine, Al-Azhar University, Cairo, Egypt. awad.abdelaziz.0505@gmail.com.
- Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
- Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
- Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Faculty of Medicine, Sohag University, Cairo, Egypt.
Förderung
- Al-Azhar University
Zitieren
APA
Hassan, M. A., Awad, A. A., Marey, A., Amin, A. M., Elshahat, A., El-Moslemani, M., Mansour, A., Ramadan, S., & Aldemerdash, M. A. (2025). Efficacy and safety of Brivaracetam as adjunctive therapy in pediatric epilepsy: A systematic review and meta-analysis. Neurological Sciences. https://doi.org/10.1007/s10072-025-08185-9
Vancouver
Hassan MA, Awad AA, Marey A, Amin AM, Elshahat A, El-Moslemani M, et al. Efficacy and safety of Brivaracetam as adjunctive therapy in pediatric epilepsy: A systematic review and meta-analysis. Neurological Sciences. 2025. doi:10.1007/s10072-025-08185-9
BibTeX
@article{Hassan2025,
author = {Hassan, Malak A and Awad, Abdelaziz A and Marey, Ahmed and Amin, Ahmed Mostafa and Elshahat, Ahmed and El-Moslemani, Mohamed and Mansour, Ahmed and Ramadan, Shrouk and Aldemerdash, Mohamed A},
title = {Efficacy and safety of Brivaracetam as adjunctive therapy in pediatric epilepsy: A systematic review and meta-analysis},
journal = {Neurological Sciences},
year = {2025},
doi = {10.1007/s10072-025-08185-9}
}
EUVIMED